Suven Life Sciences participating at the virtual SLEEP-2021 conference (10-13 June 2021), the 35th annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society.

Suven making the following three e-poster presentations through digital platform.

Abstract ID: 004 Samelisant (SUVN-G3031), Differentiating features over current treatments of narcolepsy.

Abstract ID: 005 Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist in animal models of sleep disorders.

Abstract ID: 506 Samelisant (SUVN-G3031), Baseline characteristics from a Phase 2 study evaluating efficacy and safety in patients with narcolepsy.

Disclaimer and Risk Statement: Any information on Suven Intellectual Properties, Grant of Patents and Publications related to IP/Patents provided herewith is on as-is-where-is basis and all of the statements, expectations and assumptions, including expectations and assumptions, if any, contained in this update may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Suven may not undertake to update any forward-looking statements that may be made from time to time.

Contact:

Tel: 91 40 2354 1142/ 3311/ 3315

Fax: 91 40 2354 1152

Email: info@suven.com

website: www.suven.com

(C) 2021 Electronic News Publishing, source ENP Newswire